New drug duo takes on hard-to-treat colon cancer
NCT ID NCT05382442
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 39 times
Summary
This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if these drugs can shrink tumors or slow the disease. About 254 participants will be enrolled. The study focuses on safety and how well the drugs work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Summit Therapeutics Research Site
Los Angeles, California, 90067, United States
-
Summit Therapeutics Research Site
Murrieta, California, 92562, United States
-
Summit Therapeutics Research Site
Fairfax, Virginia, 22031, United States
-
The Sixth Hospital,Sun Yat-sen University
Guanzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.